VEGFA and age-related macular degeneration: Compared to other anti-VEGF drugs such as aflibercept and ranibizumab, intravitreal injection of 6 mg brolucizumab is more effective and safer in the treatment of n-AMD, especially in the presence of IRF and/or SRF, and on participants with ≥1 serious adverse events.